FDA approves bepirovirsen, first potential functional cure for chronic hepatitis B
The FDA approved GSK's Hibsago, a six-month injection that cleared hepatitis B in about one in five trial patients.
Objective Facts
The FDA approved Hibsago (bepirovirsen), a GSK injection licensed from Ionis Pharmaceuticals, on October 20, 2026, for adults with chronic hepatitis B who have no cirrhosis, have taken nucleos(t)ide analogue antivirals for at least six months, have suppressed HBV DNA and have an HBsAg level of 3,000 IU/mL or less, according to Pharmacy Times and AJMC. The FDA calls it the first antisense oligonucleotide approved for the disease, and the agency also authorized a Roche test as a companion diagnostic to find eligible patients. In two phase 3 trials, 19% of patients given the six-month course reached functional cure, defined as undetectable virus and surface antigen for at least 24 weeks after all treatment stopped, versus 0% on placebo. The label includes boxed warnings for liver flares and dangerous drops in platelet counts, and Reuters reported GSK did not answer questions about US price or availability. Coverage from Japan and the UK focused on the earlier Japanese approval and on GSK's sales targets.
Deep Dive
Hibsago arrives after decades in which chronic hepatitis B has mostly been managed, not cleared. Reuters reported that nucleoside analogues, the common treatment, are often taken for life and rarely eliminate the virus, and that standard care brings a functional cure to only 1% to 4% of patients. More than 250 million people live with the infection worldwide, and GSK estimates about 1.7 million Americans have it, according to Alliance News. The FDA acted under Priority Review and Breakthrough Therapy designations, and BioWorld reported the decision came ahead of an October 26 target date. The headline numbers are real but bounded. Pooled trial data reported by AJMC show 19% of treated patients reached functional cure, rising to 26% in patients with HBsAg of 1,000 IU/mL or less, so roughly four in five treated patients did not. The benefit applies only to a defined slice of patients: no cirrhosis, already suppressed on antivirals, and below the HBsAg cutoff. Pharmacy Times reported adverse events in 91% of treated patients versus 73% on placebo, with grade 3 or higher events in 16% versus 3%, and the label requires weekly platelet checks. Pharmaceutical Technology noted that Citi analysts called both boxed warnings manageable, though the platelet warning was less expected. Much of the early coverage, including the 19% versus about 1% comparison, rests on GSK and FDA statements, and the 1% figure comes from outside the placebo-controlled trials. Price is the main open question. Reuters said GSK did not respond to questions on US pricing or commercial availability, and Mark Makhinson of Mount Sinai Health System told Pharmacy Times the treatment may cost more for this subset of patients but could reduce long-term care costs. Watch for the launch price, insurer coverage rules tied to the companion diagnostic test, decisions from regulators in China and Europe, and longer follow-up on whether functional cures hold. GSK has forecast peak annual sales above £2 billion, per Reuters.
Regional Perspective
In the UK, home to GSK, Alliance News reporter Eva Castanedo covered the US decision as market news, noting GSK's opening share price and the close of a separate GSK licensing deal with Hutchmed worth up to $1.30 billion. Reuters, reporting from Bengaluru and London, tied the drug to GSK's goal of more than £40 billion in annual revenue by 2031 under chief executive Luke Miels. In Asia, BioPharma Asia reported in August that Japan's Ministry of Health, Labour and Welfare approved Hibsago through its SENKU fast track designation, the first approval anywhere for the drug. The regional coverage found here differs from US trade coverage mostly in emphasis. US outlets such as Pharmacy Times and AJMC spent more space on the boxed warnings, eligibility testing and cost, while Alliance News focused on investors and BioPharma Asia on Japan's place as first to approve. No Japanese-language or Chinese coverage of the US decision turned up in searches for this story, so coverage from those countries is limited here. The local stakes are large in East Asia. BioPharma Asia reported nearly one million people in Japan live with chronic hepatitis B and the disease contributes to roughly 4,000 deaths a year there, and Reuters reported the drug is still under review in China.